Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Equity (Unaudited)

v2.4.0.8
Condensed Consolidated Statement of Equity (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
Total
Silcon
Cytochroma
Common Stock
Common Stock
Silcon
Common Stock
Cytochroma
Treasury
Additional Paid-In Capital
Additional Paid-In Capital
Silcon
Additional Paid-In Capital
Cytochroma
Acumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Noncontrolling Interests
Series D Preferred Stock
Series D Preferred Stock
Common Stock
Series D Preferred Stock
Additional Paid-In Capital
Beginning balance (audited) at Dec. 31, 2012 $ 178,894 [1]     $ 3,056     $ (7,457) $ 565,201     $ 7,356 $ (388,770) $ (492)      
Beginning balance (audited), shares at Dec. 31, 2012       305,560,763     2,293,056                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Equity-based compensation expense 7,003             7,003                
Exercise of Common Stock options 928     4       924                
Exercise of Common Stock options, shares       447,690                        
Exercise of Common Stock warrants 591     12       579                
Exercise of Common Stock warrants, shares       1,164,542                        
Series D Preferred Stock dividend                           (3,015)   (3,015)
Conversion of Series D Preferred Stock 24,386                         24,386 113 24,273
Conversion of Series D Preferred Stock, shares                             11,290,320  
Issuance of Common Stock in connection with acquisition   436 146,902   1 205     435 146,697            
Issuance of Common Stock in connection with acquisition, shares         64,684 20,517,030                    
Net loss attributable to common shareholders before preferred stock dividend (37,609)                     (37,609)        
Net loss attributable to noncontrolling interests (1,506)                       (1,506)      
Other comprehensive loss (4,526)                   (4,526)          
Ending balance (unaudited) at Jun. 30, 2013 $ 312,484 [1]     $ 3,391     $ (7,457) $ 742,097     $ 2,830 $ (426,379) $ (1,998)      
Ending balance (unaudited), shares at Jun. 30, 2013       339,045,029     2,293,056                  
[1] As of June 30, 2013 and December 31, 2012, total assets include $6.0 million and $5.6 million, respectively, and total liabilities include $7.8 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities are those as to which there is no recourse against us. Refer to Note 5.